trending Market Intelligence /marketintelligence/en/news-insights/trending/5TSXhC90TRvuaMtLpeRkfA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Omega raises $438M via venture capital fund to invest in life sciences companies

Key Credit Risk Factors When Assessing Banks In The Context Of COVID-19

Street Talk Episode 61 - Investors debate if U.S. banks have enough capital in post COVID world

You Down With PPP? Consider The Risks

Street Talk Episode 60 - You Down With PPP? Consider The Risks

Omega raises $438M via venture capital fund to invest in life sciences companies

Boston, Mass.-based investment company Omega Fund Management LLC raised $438 million in capital commitments via its sixth venture capital fund named Omega Fund VI LP.

The company said it will continue its strategy of creating and investing in life sciences companies targeting urgent medical needs.

Omega said investments from Fund VI will use various investment approaches, including company founding and creation, early venture rounds, late-stage public investing and direct secondary transactions.

Omega Fund is an investment company that targets biotechnology and medical device businesses based in North America and Western Europe. According to the company's press release dated Dec. 11, Omega Funds has raised more than $1 billion to invest in entrepreneurs developing products across different therapeutic areas including oncology, immunology, rare diseases and precision medicine since 2004.